NYSE:MED Medifast (MED) Stock Price, News & Analysis → Log Into Marc's $5,000 System Today (From Chaikin Analytics) (Ad) Free MED Stock Alerts $24.80 +1.97 (+8.63%) (As of 04:10 PM ET) Add Compare Share Share Today's Range$22.70▼$24.9450-Day Range$22.76▼$38.3252-Week Range$22.35▼$109.52Volume830,157 shsAverage Volume414,512 shsMarket Capitalization$271.31 millionP/E Ratio4.00Dividend YieldN/APrice Target$53.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Medifast alerts: Email Address Medifast MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside117.0% Upside$53.50 Price TargetShort InterestBearish30.42% of Float Sold ShortDividend StrengthN/ASustainability-4.07Upright™ Environmental ScoreNews Sentiment0.63Based on 5 Articles This WeekInsider TradingSelling Shares$159,850 Sold Last QuarterProj. Earnings Growth115.79%From $0.95 to $2.05 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.08 out of 5 starsConsumer Staples Sector36th out of 135 stocksMiscellaneous Food Preparations & Kindred Products Industry1st out of 4 stocks 3.0 Analyst's Opinion Consensus RatingMedifast has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageMedifast has only been the subject of 1 research reports in the past 90 days.Read more about Medifast's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted30.42% of the float of Medifast has been sold short.Short Interest Ratio / Days to CoverMedifast has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Medifast has recently increased by 3.85%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMedifast does not currently pay a dividend.Dividend GrowthMedifast has only been increasing its dividend for 1 years. Previous Next 1.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMedifast has received a -4.19% net impact score from Upright. The largest negative impact of Medifast in category "GHG emissions" seems to be driven mostly by its "Meal replacement soups", "Meal replacement bars", "Meal replacement drinks", and "Protein bars" products. See details.Environmental SustainabilityThe Environmental Impact score for Medifast is -4.07. Previous Next 2.6 News and Social Media Coverage News SentimentMedifast has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Consumer Staples companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Medifast this week, compared to 4 articles on an average week.Search Interest23 people have searched for MED on MarketBeat in the last 30 days. This is an increase of 188% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Medifast to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medifast insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $159,850.00 in company stock.Percentage Held by InsidersOnly 2.50% of the stock of Medifast is held by insiders.Percentage Held by Institutions95.51% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Medifast's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Medifast are expected to grow by 115.79% in the coming year, from $0.95 to $2.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medifast is 3.98, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.47.Price to Earnings Ratio vs. SectorThe P/E ratio of Medifast is 3.98, which means that it is trading at a less expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 18.66.Price to Book Value per Share RatioMedifast has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Medifast's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.Click here for the full story… About Medifast Stock (NYSE:MED)Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.Read More MED Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MED Stock News HeadlinesMay 28 at 8:41 AM | marketbeat.comLifeMD Can Surge on Its GLP-1 Offerings (MED)LifeMD is a leading telehealth provider that investors should take note of; the company is entering the GLP-1 market, and its stock could soar as a resultMay 24, 2024 | seekingalpha.comMedifast: Significant Undervaluation Even As Struggles PersistMay 22, 2024 | stockhouse.comINVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Medifast, Inc. and Encourages Investors to Contact the FirmMay 22, 2024 | finance.yahoo.comInvestors Could Be Concerned With Medifast's (NYSE:MED) Returns On CapitalMay 20, 2024 | investorplace.comInvest in the Underestimated: 7 Bargain Stocks Poised to Prove Wall Street WrongMay 20, 2024 | finance.yahoo.comMedifast Continues Business Transformation, Launching National Marketing Campaign Promoting its Holistic Offering for Customers Utilizing and Considering Weight Loss MedicationsMay 20, 2024 | businesswire.comMedifast Continues Business Transformation, Launching National Marketing Campaign Promoting its Holistic Offering for Customers Utilizing and Considering Weight Loss MedicationsMay 20, 2024 | americanbankingnews.comZacks Research Weighs in on Medifast, Inc.'s Q2 2024 Earnings (NYSE:MED)May 18, 2024 | sg.finance.yahoo.comMED Jun 2024 65.000 putMay 16, 2024 | bizjournals.comMedifast closes Maryland warehouse, lays off 62 workersMay 13, 2024 | investorplace.comPocket-Sized Powerhouses: 7 Small-Cap Value Stocks Ready to RoarMay 9, 2024 | finance.yahoo.comQ1 2024 LifeMD Inc Earnings CallMay 6, 2024 | finance.yahoo.comEarnings To Watch: Nature's Sunshine (NATR) Reports Q1 Results TomorrowMay 1, 2024 | msn.comMedifast Just Hit Its 20th 5-Year Low. Are You Smart/Dumb Enough to Buy?May 1, 2024 | finance.yahoo.comMedifast, Inc. (NYSE:MED) Q1 2024 Earnings Call TranscriptMay 1, 2024 | ca.investing.comOlaplex Earnings: What To Look For From OLPXMay 1, 2024 | finance.yahoo.comMedifast First Quarter 2024 Earnings: EPS Misses ExpectationsApril 30, 2024 | za.investing.comMedifast stock plunges on earnings miss, weak outlookApril 30, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Consumer Cyclical Stocks: The Chefs’ Warehouse (CHEF), Medifast (MED) and Marine Products (MPX)April 30, 2024 | finance.yahoo.comWhy Medifast (MED) Shares Are Trading Lower TodayApril 30, 2024 | investorplace.comWhy Is Medifast (MED) Stock Down 20% Today?April 30, 2024 | msn.comMedifast Reports Mixed Results, Joins Coursera, Chegg And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionApril 30, 2024 | finance.yahoo.comMedifast Inc (MED) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges with ...April 30, 2024 | finance.yahoo.comQ1 2024 Medifast Inc Earnings CallApril 29, 2024 | investorplace.comMED Stock Earnings: Medifast Misses EPS, Beats Revenue for Q1 2024See More Headlines Receive MED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/29/2024Today5/28/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorConsumer Staples Industry Miscellaneous food preparations & kindred products Sub-IndustryPersonal Products Current SymbolNYSE:MED CUSIP58470H10 CIK910329 Webwww.medifast1.com Phone(410) 581-8042Fax410-581-8070Employees634Year FoundedN/APrice Target and Rating Average Stock Price Target$53.50 High Stock Price Target$82.00 Low Stock Price Target$25.00 Potential Upside/Downside+115.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$6.20 Trailing P/E Ratio4.00 Forward P/E Ratio26.11 P/E GrowthN/ANet Income$99.42 million Net Margins7.55% Pretax Margin9.70% Return on Equity36.64% Return on Assets23.16% Debt Debt-to-Equity RatioN/A Current Ratio2.84 Quick Ratio2.25 Sales & Book Value Annual Sales$1.07 billion Price / Sales0.25 Cash Flow$11.81 per share Price / Cash Flow2.10 Book Value$18.50 per share Price / Book1.34Miscellaneous Outstanding Shares10,940,000Free Float10,664,000Market Cap$271.31 million OptionableOptionable Beta1.19 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Daniel R. Chard (Age 59)Executive Chairman & CEO Comp: $1.94MMr. James P. Maloney CPA (Age 56)Chief Financial Officer Comp: $823.91kMr. Anthony E. Tyree (Age 59)Chief Business Operations Officer Comp: $655.86kMr. Jason L. Groves Esq. (Age 53)Executive VP, General Counsel & Corporate Secretary Comp: $669.51kMr. Nicholas M. Johnson (Age 44)Chief Field Operations Officer Comp: $696.4kMr. Jonathan Barrett MacKenzie (Age 52)VP of Finance & Chief Accounting Officer Mr. Steven ZenkerVice President of Investor RelationsMs. Claudia C. Greninger (Age 51)Chief Human Resources Officer More ExecutivesKey CompetitorsUSANA Health SciencesNYSE:USNANu Skin EnterprisesNYSE:NUSNature's Sunshine ProductsNASDAQ:NATRVeruNASDAQ:VERUEstée Lauder CompaniesNYSE:ELView All CompetitorsInsiders & InstitutionsBurney Co.Bought 20,064 shares on 5/22/2024Ownership: 0.183%Swedbank ABBought 3,000 shares on 5/21/2024Ownership: 0.027%Virtu Financial LLCBought 5,975 shares on 5/20/2024Ownership: 0.055%Walleye Trading LLCSold 1,000 shares on 5/17/2024Ownership: 0.000%California State Teachers Retirement SystemSold 591 shares on 5/16/2024Ownership: 0.099%View All Insider TransactionsView All Institutional Transactions MED Stock Analysis - Frequently Asked Questions Should I buy or sell Medifast stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MED, but not buy additional shares or sell existing shares. View MED analyst ratings or view top-rated stocks. What is Medifast's stock price target for 2024? 2 analysts have issued 12 month price targets for Medifast's shares. Their MED share price targets range from $25.00 to $82.00. On average, they anticipate the company's share price to reach $53.50 in the next year. This suggests a possible upside of 117.0% from the stock's current price. View analysts price targets for MED or view top-rated stocks among Wall Street analysts. How have MED shares performed in 2024? Medifast's stock was trading at $67.22 at the beginning of 2024. Since then, MED shares have decreased by 63.3% and is now trading at $24.66. View the best growth stocks for 2024 here. When is Medifast's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our MED earnings forecast. How were Medifast's earnings last quarter? Medifast, Inc. (NYSE:MED) announced its earnings results on Monday, April, 29th. The specialty retailer reported $0.66 earnings per share for the quarter, missing analysts' consensus estimates of $0.78 by $0.12. The specialty retailer had revenue of $174.74 million for the quarter, compared to analyst estimates of $168.90 million. Medifast had a trailing twelve-month return on equity of 36.64% and a net margin of 7.55%. Medifast's revenue for the quarter was down 49.9% on a year-over-year basis. During the same period in the prior year, the firm earned $3.67 earnings per share. How often does Medifast pay dividends? What is the dividend yield for Medifast? Medifast declared a quarterly dividend on Thursday, September 7th. Investors of record on Tuesday, September 19th will be paid a dividend of $1.65 per share on Tuesday, November 7th. This represents a $6.60 annualized dividend and a yield of 26.76%. The ex-dividend date is Monday, September 18th. Read our dividend analysis for MED. What ETFs hold Medifast's stock? ETFs with the largest weight of Medifast (NYSE:MED) stock in their portfolio include Invesco S&P SmallCap High Dividend Low Volatility ETF (XSHD), Invesco S&P SmallCap Consumer Staples ETF (PSCC) and Global X Health & Wellness ETF (BFIT). What guidance has Medifast issued on next quarter's earnings? Medifast issued an update on its second quarter 2024 earnings guidance on Monday, April, 29th. The company provided earnings per share guidance of 0.050-0.400 for the period, compared to the consensus EPS estimate of 0.780. The company issued revenue guidance of $150.0 million-$170.0 million, compared to the consensus revenue estimate of $168.9 million. What is Daniel Chard's approval rating as Medifast's CEO? 44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Medifast own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM). Who are Medifast's major shareholders? Medifast's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.27%), Jacobs Levy Equity Management Inc. (1.59%), PEAK6 Investments LLC (0.00%), Principal Financial Group Inc. (0.59%), Allspring Global Investments Holdings LLC (0.39%) and Inspire Advisors LLC (0.30%). Insiders that own company stock include Andrea B Thomas, Constance J Hallquist, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes and Scott Schlackman. View institutional ownership trends. How do I buy shares of Medifast? Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:MED) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDigitizing the $11T commodities sector with one tiny stockResource Stock DigestWARNING about the death of the U.S. dollar…Colonial MetalsThe only AI company to buyPorter & CompanyBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsIs Artificial Intelligence the Biggest Bubble in History?InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medifast, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.